The fibroblast hormone Endotrophin is a biomarker of mortality in chronic diseases
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Fibroblast activity, measured by circulating endotrophin (PROC6), is linked to increased mortality risk across many chronic diseases. Targeting fibroblast activity may offer new therapeutic strategies for improving patient outcomes.
Area Of Science
- Biomedical Science
- Pathology
- Clinical Research
Background
- Fibrosis, driven by fibroblast activity, contributes significantly to morbidity and mortality in chronic diseases.
- Endotrophin (PROC6), a marker of activated fibroblasts, is implicated in fibrotic tissue remodeling and associated with mortality risk.
- Previous studies suggest a link between circulating endotrophin and increased mortality in various chronic conditions.
Purpose Of The Study
- To systematically review and meta-analyze the association between circulating endotrophin (PROC6) levels and all-cause mortality.
- To evaluate if fibroblast activity, quantified by PROC6, is an independent predictor of mortality across diverse non-communicable chronic diseases (NCCDs).
Main Methods
- A systematic literature review of original papers published between 2012 and January 2023.
- An Individual Patient Data (IPD) meta-analysis including sixteen cohorts (N = 15,205) of patients with various NCCDs.
- Statistical analysis adjusted for age, sex, and BMI, evaluating the hazard ratio for 3-year all-cause mortality associated with PROC6 levels.
Main Results
- The IPD meta-analysis revealed a summary hazard ratio of 2.10 (95% CI 1.75-2.52) for 3-year all-cause mortality for a 2-fold increase in PROC6.
- Some heterogeneity was observed between the included studies (I²=70%).
- Circulating endotrophin (PROC6) was independently associated with mortality across a broad range of NCCDs.
Conclusions
- Fibroblast activity, as indicated by circulating endotrophin, is an independent predictor of mortality in patients with non-communicable chronic diseases.
- Interstitial tissue remodeling and fibroblast activity play a crucial role in adverse clinical outcomes, irrespective of the specific disease.
- Endotrophin presents a potential therapeutic target for drug developers aiming to mitigate mortality in chronic diseases.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...